

Information Governance Department
Blackpool Victoria Hospital
Whinney Heys Road
Blackpool
Lancashire
FY3 8NR

bfwh.pso@nhs.net

24th February 2020

Our ref: FOI 03540

Dear

Thank you for your request for information.

Your Request & Our Response

I have a Freedom of Information request regarding biologics and biosimilar prescribing in **dermatology**.

Could you please provide me with the following numbers of patients treated in the last 12 months with the following drugs.

If you are unable to provide the information above with specific reference to dermatology then please provide me with the numbers of patients treated in the last 12 months with the below drugs, regardless of disease/indication.

Unfortunately our systems do not record the clinical indication and the figures below are not a record of what has been prescribed but what has been dispensed. These are the number of patients who have had a transactions recorded on our systems in the last 12 months where the consultants specialty is Dermatology

Adalimumab [Amgevita] -131 Adalimumab [Hulio] - 0 Adalimumab [Humira] - 36 Adalimumab [Hvrimoz] - 0 Adalimumab [lmraldi] - 0 Apremilast [Otezla] - 27 Brodalumab [Kyntheum] - 4 Certolizumab [Cimzia] - 4 Dimethyl fumarate [Skilarence] - 10 Dupilumab [Dupixient] - 51 Etanercept [Benepali] - 2 Etanercept [Enbrel] - 4 Etanercept [Erelzi] - 0 Golimumab [Simponi] - 0 Guselkumab [Tremfya]

Chairman: Pearse Butler

Chief Executive: Kevin McGee (Interim)

RESEARCH MATTERS AND SAVES LIVES - TODAY'S RESEARCH IS TOMORROW'S CARE

Blackpool Teaching Hospitals is a Centre of Clinical and Research Excellence providing quality up to date care. We are actively involved in undertaking research to improve treatment of our patients. A member of the healthcare team may discuss current clinical trials with you.







Infliximab [Flixabi] - 9 - 0 Infliximab [Inflectra] Infliximab [Remicade] - 8 Infliximab [Remsima] - 3 Ixekizumab [Taltz] - 3 Risankizumab [Skyrizi] - 1 - 37 Secukinumab [Cosentyx] Tildrakizumab [llumetri] - 0 Tocilizumab [Ro Actemra] - 0 - 0 Upadacitinib [Rinvoq] Ustekinumab [Stelara] - 103

The information in this response is provided under the terms of the Open Government Licence. Please see here for more information:

http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/

The following link is a customer satisfaction survey if you would like to leave feedback:

http://www.bfwh.nhs.uk/our-services/hospital-services/information-governance/foi-questionnaire/

If you are dissatisfied with our response to your request for access to information you may ask us to carry out an internal review. You should do this by writing to:

The Information Governance Manager
Blackpool Teaching Hospitals NHS Foundation Trust
Blackpool Victoria Hospital
Whinney Heys Rd
Blackpool
FY3 8NR

Email: bfwh.pso@nhs.net

If you remain unhappy, you may make a complaint to the Information Commissioner's Office.

Yours Sincerely,

Stephen Connor Freedom of Information Manager